ABVC BioPharma (ABVC) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
SCYNEXIS (SCYX) has outperformed ABVC BioPharma (ABVC) over the past year, losing 56.3% versus a loss of 67.8%. Over five years, SCYX leads with a -96.0% price change compared with -97.3% for ABVC. SCYNEXIS is the larger company by market cap ($23.7 million vs $23.4 million), about 1.0 times the size.
SCYNEXIS converts more of its revenue into profit, with a net margin of -41.8% versus -2671.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | SCYX |
|---|---|---|
| Share price | $0.8663 | $2.38 |
| Market cap | $23.37M | $23.69M |
| 1-day change | -1.56% | -8.64% |
| YTD return | -59.33% | -52.93% |
| 1-year return | -67.80% | -56.25% |
| 5-year return | -97.29% | -96.00% |
| EPS (TTM) | $-0.20 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | $20.60M |
| Revenue growth (YoY) | -41.91% | +449.95% |
| Net income (latest FY) | $-7.91M | $-8.61M |
| Operating margin | -2415.97% | -78.03% |
| Net margin | -2671.81% | -41.79% |
| 52-week high | $2.87 | $9.12 |
| 52-week low | $0.707 | $2.30 |
| Distance from 52-week high | -69.82% | -73.90% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1426.47% |
| Average volume | 81.92K | 225.27K |
| Shares outstanding | 26.98M | 9.95M |
| Employees | 16 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed ABVC by 11.5 percentage points over the past year.
- SCYNEXIS is more profitable, keeping -41.8 cents of every revenue dollar as net income versus -2671.8 cents for ABVC BioPharma.
- SCYNEXIS grew revenue faster in its latest fiscal year (+449.95% vs -41.91%).
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
ABVC vs SCYX FAQ
Which is bigger, ABVC BioPharma or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $23.69M compared with $23.37M for ABVC BioPharma (ABVC).
Which stock has performed better over the past year, ABVC or SCYX?
SCYX returned -56.25% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.